Kestra Investment Management LLC Purchases Shares of 92 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Kestra Investment Management LLC purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 92 shares of the company’s stock, valued at approximately $38,000.

Several other large investors have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC raised its holdings in IDEXX Laboratories by 465.3% in the 4th quarter. Venturi Wealth Management LLC now owns 571 shares of the company’s stock valued at $236,000 after acquiring an additional 470 shares in the last quarter. D.A. Davidson & CO. raised its holdings in IDEXX Laboratories by 2.8% in the 4th quarter. D.A. Davidson & CO. now owns 1,674 shares of the company’s stock valued at $692,000 after acquiring an additional 45 shares in the last quarter. Truist Financial Corp raised its holdings in IDEXX Laboratories by 13.9% in the 4th quarter. Truist Financial Corp now owns 27,784 shares of the company’s stock valued at $11,487,000 after acquiring an additional 3,382 shares in the last quarter. CIBC Asset Management Inc raised its holdings in shares of IDEXX Laboratories by 3.1% in the 4th quarter. CIBC Asset Management Inc now owns 26,366 shares of the company’s stock worth $10,901,000 after buying an additional 788 shares in the last quarter. Finally, J.W. Cole Advisors Inc. raised its holdings in shares of IDEXX Laboratories by 4.5% in the 4th quarter. J.W. Cole Advisors Inc. now owns 2,760 shares of the company’s stock worth $1,141,000 after buying an additional 118 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on IDXX. Barclays increased their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Bank of America increased their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Morgan Stanley dropped their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Finally, StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, February 5th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Trading Down 0.0 %

IDXX stock opened at $452.77 on Friday. The business has a fifty day moving average price of $431.92 and a 200 day moving average price of $452.40. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39. The stock has a market capitalization of $37.08 billion, a price-to-earnings ratio of 42.43, a P/E/G ratio of 3.41 and a beta of 1.37. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 13,330 shares of company stock valued at $6,161,276 in the last three months. Corporate insiders own 2.11% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.